Skip to Content Skip to Search

GSK at a glance

Here are some of our key achievements in pursuing our purpose to get ahead of disease.

Multiple Myeloma cells

We develop cancer medicines with life-changing potential for patients including ovarian cancer, endometrial cancer and multiple myeloma.

COVID virus cell

We have developed a new monoclonal antibody treatment for COVID-19. Monoclonal antibodies work in a similar way to the human immune system and can help people who do not have a strong natural immune response to a virus.

HIV cell

We delivered three major product approvals in 2021 for endometrial cancer, COVID-19 and HIV. 

Shingles cell

Our vaccines portfolio is the broadest in the industry, helping protect people from meningitis, shingles, flu, polio, measles and many more.

Immuno Oncology science image

We have three marketed cancer therapies, with a further nine assets in development.

Scientist in a smart lab

We're focusing on antimicrobial resistance and drug-resistant infections with 28 R&D projects targeting priority pathogens including those deemed ‘critical’ and ‘urgent’ by the World Health Organization.  

Meningitis vaccine patient

Two million of our vaccines are administered every day, and 40% of the world’s children receive a GSK vaccine each year.

DNA spiral enveloped in polygonal pattern

Since 2017, we’ve delivered 13 major approvals and more than doubled the number of potential new vaccines and medicines we have in Phase 3 and registration, to 23.

Scientist examining a vial

Our ground-breaking malaria vaccine is the first and only vaccine shown in long-term clinical trials to reduce malaria in children.

Back to top